BioCentury
ARTICLE | Company News

Aslan, CSL deal

May 19, 2014 7:00 AM UTC

Aslan gained worldwide rights to CSL334 ( ASLAN004) from CSL. The human mAb against IL-13 receptor alpha 1 ( IL-13RA1; IL-13Ra; CD213A1) is in preclinical testing to treat asthma. Aslan will fund a...